Leucovorin Prescriptions Surge Despite Retracted Autism Trial and Lack of Evidence

Leucovorin Prescriptions Spike After White House Briefing

In 2025, a White House briefing on autism led to a significant increase in prescriptions for leucovorin, a form of folic acid, despite a lack of strong clinical evidence supporting its use for autism. A study from Brown University found that prescriptions surged shortly after the briefing, highlighting the influence of political announcements on medical practices.

Retracted Trial and Lack of Evidence

The largest clinical trial supporting leucovorin's use for autism was retracted in February 2026 due to methodological flaws, including inadequate blinding and statistical inconsistencies. NPR reported that the history of leucovorin as a potential autism treatment is fraught with insufficient evidence, and experts caution against its widespread use without more rigorous studies.

Building a Better Clinical Trial Infrastructure

To address the evidence gap in autism support, the University of California Health system received $17 million to establish the IMPACT-LA clinical trial network. This initiative, detailed on their website, aims to improve the quality and reliability of autism research by focusing on individualized support strategies. Meanwhile, a study in Nature proposed a machine learning algorithm, Q-Finder, to predict which individuals might respond to bumetanide, another experimental treatment.

The Controversy Continues

The promotion of leucovorin by political entities contrasts sharply with the scientific consensus, which emphasizes the need for more robust evidence. The retraction of the major leucovorin trial and the lack of supporting data underscore the challenges in developing effective support strategies for autistic individuals.